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Abstract
Background Most randomized controlled trials (RCTs)
that have compared neoadjuvant chemoradiation followed
by surgery with surgery alone for locally advanced
esophageal cancer have shown no difference in survival
between the two treatments. Meta-analyses on neoadjuvant
chemoradiation in esophageal cancer, however, are
discordant.
Methods For the present study, published meta-analyses
on neoadjuvant chemoradiation for esophageal cancer were
identiﬁed from the PubMed database and critically
appraised in order to make a judgment on the applicability
of neoadjuvant chemoradiation in clinical practice and
decision making.
Results Two of the six meta-analyses examined did not
show a signiﬁcant survival beneﬁt in patients with resect-
able esophageal cancer. Differences in the studies included
and statistical methods applied might account for this.
Moreover, there was heterogeneity between the RCTs
included in the meta-analyses with regard to the patients
included, tumor histology, and radiotherapy and
chemotherapy regimes. Also, surgical technique was not
uniform. No data on individual patients were available for
most meta-analyses. The RCTs included in the meta-
analyses were of inadequate sample size. All were started
in the nineties, and hence methods for diagnosis, staging,
treatment delivery, and outcome measurement reﬂect
clinical practice during that decade.
Conclusions The current data on neoadjuvant chemora-
diation for esophageal cancer strongly indicate the need for
designing future high-quality trials that will contribute to a
better understanding of the role of neoadjuvant treatment
for resectable cancer of the esophagus and help to identify
patient subgroups that would beneﬁt most.
Introduction
Esophageal cancer is the ninth most frequent cancer
worldwide and its incidence is rising. In recent decades
knowledge of cancer has improved dramatically, but this
has led to only a small improvement in survival rates of
patients with esophageal cancer. A radical esophagectomy
is by many considered to be the best treatment that can
offer long-term survival with good locoregional control.
More than half a century after surgery for esophageal
cancer ﬁrst took off, most clinicians now strongly feel
that a multidisciplinary approach is necessary to further
improve the outlook for patients with this disease. One
such approach is preoperative chemoradiotherapy (CRT),
a strategy that has received much attention recently. Quite
a number of phase II studies and randomized phase III
trials (RCTs) on neoadjuvant CRT as compared to surgery
alone have been published. Also, the outcome data of
these studies have been combined and reported as
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critically appraised trials on neoadjuvant CRT in esoph-
ageal cancer.
What is a meta-analysis?
A meta-analysis is a review in which bias has been reduced
by the systematic identiﬁcation, appraisal, synthesis and, if
relevant, statistical aggregation of all relevant studies on a
speciﬁc topic according to a predetermined and explicit
method [1, 2]. The advantages of meta-analyses are that
the process of review generally is transparent, valid, and
reproducible. Meta-analyses can be appealing because
‘‘signiﬁcance’’ can be attained when small groups are
pooled into big ones and new scientiﬁc hypotheses, that
had inconclusive results or that had not been originally
tested, can be examined in subgroups. Such reviews of
well-performed, adequately powered randomized con-
trolled trials are considered to be the highest level of evi-
dence. A meta-analysis can thus serve as an efﬁcient
method to get a quick and valid insight into a clinical
question and may serve as a policy foundation for evi-
dence-based practice guidelines.
Discordance of meta-analyses
However, meta-analyses on the same topic can be dis-
cordant [3, 4]. They may differ with respect to the
direction of the estimated effect or, if the direction is the
same, with respect to the effect’s magnitude or statistical
signiﬁcance. This is the case with meta-analyses published
on neoadjuvant CRT in esophageal cancer. Two of the six
published reviews do not show a signiﬁcant survival
beneﬁt in patients with resectable esophageal cancer
(Table 1). This apparent lack of beneﬁt may lead to dif-
ferences in translation of the available evidence for the
use of preoperative CRT. For example, in the United
States and Australia, CRT followed by surgery is now
considered to be standard treatment for resectable esoph-
ageal cancer, whereas in the Netherlands, surgery alone is
still favored, and neoadjuvant CRT is only applied within
the setting of a clinical trial [5].
It is therefore important to gain insight into the methods
behind the published reviews in order to make judgments
on the applicability of the ﬁndings in clinical practice and
decision making. Jadad et al. summarized several sources
of discordance among meta-analyses [3], including dif-
ferences in the clinical question, selection of studies and
inclusion, data extraction, ability to combine studies, and
statistical methods for data analysis. In the following
paragraphs we discuss these issues in detail, within the
light of the currently available trials on neoadjuvant CRT
in esophageal cancer.
T
a
b
l
e
1
C
h
a
r
a
c
t
e
r
i
s
t
i
c
s
o
f
t
h
e
m
e
t
a
-
a
n
a
l
y
s
e
s
t
h
a
t
i
n
v
e
s
t
i
g
a
t
e
d
t
h
e
v
a
l
u
e
o
f
n
e
o
a
d
j
u
v
a
n
t
c
h
e
m
o
r
a
d
i
a
t
i
o
n
i
n
r
e
s
e
c
t
a
b
l
e
e
s
o
p
h
a
g
e
a
l
c
a
n
c
e
r
M
e
t
a
-
a
n
a
l
y
s
i
s
C
h
a
r
a
c
t
e
r
i
s
t
c
s
U
r
s
c
h
e
l
a
n
d
V
a
s
a
n
[
9
]
K
a
k
l
a
m
a
n
o
s
e
t
a
l
.
[
8
]
F
i
o
r
i
c
a
e
t
a
l
.
[
7
]
M
a
l
t
h
a
n
e
r
e
t
a
l
.
[
3
5
]
G
r
e
e
r
e
t
a
l
.
[
1
6
]
G
e
b
s
k
i
e
t
a
l
.
[
6
]
S
t
u
d
y
p
e
r
i
o
d
N
o
t
s
t
a
t
e
d
1
9
6
0
–
2
0
0
2
1
9
7
0
–
2
0
0
2
1
9
6
6
–
2
0
0
3
1
9
6
6
–
2
0
0
3
1
9
8
0
o
n
w
a
r
d
P
r
i
m
a
r
y
e
n
d
p
o
i
n
t
O
R
1
-
2
-
3
y
e
a
r
s
u
r
v
i
v
a
l
A
b
s
o
l
u
t
e
%
d
i
f
f
e
r
e
n
c
e
i
n
2
-
y
e
a
r
s
u
r
v
i
v
a
l
O
R
3
-
y
e
a
r
o
v
e
r
a
l
l
m
o
r
t
a
l
i
t
y
R
R
o
f
d
e
a
t
h
a
t
1
y
e
a
r
R
R
o
f
d
e
a
t
h
H
R
a
l
l
-
c
a
u
s
e
m
o
r
t
a
l
i
t
y
a
n
d
a
b
s
o
l
u
t
e
2
-
y
e
a
r
s
u
r
v
i
v
a
l
M
a
i
n
o
u
t
c
o
m
e
s
C
o
n
c
u
r
r
e
n
t
C
R
T
i
m
p
r
o
v
e
s
3
-
y
e
a
r
s
u
r
v
i
v
a
l
,
t
r
e
n
d
t
o
w
a
r
d
i
n
c
r
e
a
s
e
d
t
r
e
a
t
m
e
n
t
m
o
r
t
a
l
i
t
y
f
o
r
C
R
T
C
R
T
d
o
e
s
n
o
t
i
m
p
r
o
v
e
s
u
r
v
i
v
a
l
;
n
o
n
s
i
g
n
i
ﬁ
c
a
n
t
i
n
c
r
e
a
s
e
i
n
t
r
e
a
t
m
e
n
t
-
r
e
l
a
t
e
d
m
o
r
t
a
l
i
t
y
C
R
T
i
m
p
r
o
v
e
s
3
-
y
e
a
r
s
u
r
v
i
v
a
l
;
i
n
c
r
e
a
s
e
d
p
o
s
t
o
p
e
r
a
t
i
v
e
m
o
r
t
a
l
i
t
y
N
o
d
i
f
f
e
r
e
n
c
e
i
n
r
i
s
k
o
f
m
o
r
t
a
l
i
t
y
a
t
1
y
e
a
r
f
o
r
C
R
T
,
b
u
t
t
h
e
r
e
w
a
s
a
d
i
f
f
e
r
e
n
c
e
a
t
3
y
e
a
r
s
C
R
T
d
o
e
s
n
o
t
i
m
p
r
o
v
e
o
v
e
r
a
l
l
s
u
r
v
i
v
a
l
S
i
g
n
i
ﬁ
c
a
n
t
s
u
r
v
i
v
a
l
b
e
n
e
ﬁ
t
o
f
C
R
T
R
C
T
r
a
n
d
o
m
i
z
e
d
c
o
n
t
r
o
l
l
e
d
t
r
i
a
l
,
C
R
T
c
h
e
m
o
r
a
d
i
o
t
h
e
r
a
p
y
,
O
R
o
d
d
s
r
a
t
i
o
,
R
R
r
e
l
a
t
i
v
e
r
i
s
k
,
H
R
h
a
z
a
r
d
r
a
t
i
o
World J Surg (2009) 33:2606–2614 2607
123Research question, search strategy, inclusion and
exclusion criteria
The ﬁrst step is to examine if the different reviews address
exactly the same question under consideration. All 6 meta-
analyses on neoadjuvant CRT in esophageal cancer
addressed the following research question: ‘‘Is there a
beneﬁt of preoperative CRT compared with surgery alone
for resectable esophageal cancer?’’
Next, a search strategy was undertaken to identify all
possible studies that should be included in the meta-anal-
ysis. Differences in search strategy (e.g., by using different
search terms to screen databases) may reﬂect differences in
included trials among reviews. Ideally, researchers search
all available sources of information to identify all relevant
studies addressing a particular research question. Medline
(on PubMed), Cancerlit, Cochrane Library, and EMBASE
are generally screened using key words, and manual sear-
ches (cross checking reference lists or abstract books from
major congresses) are also done in most cases.
As shown in Table 2, not all reviews have included the
same primary trials. It is of importance to determine which
search and selection process is least likely to be biased. The
publication by Gebski et al. includes data from three recent
studies that could not be incorporated in the earlier pub-
lished meta-analyses [6]. The inclusion of more studies
should not lead to systematically different conclusions, but
it does lead to increased precision (reduced random effect).
The review by Urschel et al. included two studies published
as an abstract only, whereas other meta-analyses limited
their inclusion criteria to peer-reviewed, full articles [7–9].
Only in one meta-analysis, were unpublished data from
a thesis incorporated and used for statistical pooling [6].
Although one study found that there were no substantial
differences in study quality between published and
unpublished clinical research studies, another suggested
that intervention effects reported in journals were 33%
greater than those reported in doctoral dissertations [10].
Meta-analyses limited to published trials, compared with
those that included both published and so-called ‘‘gray
literature’’ (literature difﬁcult to locate or retrieve), over-
estimated the treatment effect by an average of 12% [11].
In conclusion, including unpublished reports tends to yield
less bias and should be aimed at.
It should also be kept in mind that not including trials
that haven’t been published because of a negative result
could well lead to bias (publication bias). Two meta-
analyses investigated the likelihood that publication bias
was present. One study did not suggest publication bias
against negative trials [9]. Another test for potential pub-
lication bias yielded an estimate of nine potentially
unpublished studies from chemoradiotherapy [6].
Somereviewsexcludednon-Englishlanguagestudies[6],
and this also introduces a potential source of bias, as there is
noevidencetosupportdifferencesinqualitybetweenstudies
reported in the English literature versus non-English lan-
guage publications [12–14]. Why Kaklamanos et al. exclu-
ded the study of Apinop et al. from their review is unclear
Table 2 Meta-analyses on neoadjuvant chemoradiotherapy for esophageal cancer and randomized controlled trials (RCTs) included (?) or not
included (–) in their analyses
Meta-analysis
Urschel
and
Vasan [9]
Kaklamanos
et al. [8]
Fiorica
et al. [7]
Malthaner
et al. [35]
Greer
et al. [16]
Gebski
et al. [6]
RCT
Nygaard et al. [36] ?? ? ? ? ?
Le Prise et al. [37] ?? ? ? ? ?
Apinop et al. [15] ? – ?? ? ?
Walsh et al. [30] ?? ? ? ? ?
Bosset et al. [20] ?? ? ? ? ?
Law 1998
a ? –– – – –
Urba et al. [29] ?? ? ? ? ?
Walsh [38]
a ? –– – – –
Burmeister et al. [21] ?
a –– – – ?
a
Lee et al. [26]– – – – – ?
Tepper et al. [24]– – – – – ?
Walsh [32]
b –– – – – ?
a Abstract
b Unpublished thesis
2608 World J Surg (2009) 33:2606–2614
123[8, 15]. Although the latter study only included patients
with locally advanced esophageal cancer, the tumors were
otherwise operable.
To further minimize bias, the search and selection for
potential trials to be included in meta-analyses should be
done by two or more independent investigators, something
that was done in only one of the meta-analyses dealt with
here [16].
Data extraction and analysis
Meta-analyses of data on individual patients are considered
the yardstick against which other reviews of RCTs should
be measured. Data on individual patients afford the
opportunity for reviewers to measure outcomes more uni-
formly, to compare outcomes measured at different times,
to use intention-to-treat analysis, to conduct ﬂexible sub-
group analysis, and to update follow-up information [2].
Despite multiple attempts made by Greer et al. and Ka-
kalamanos et al., they were unsuccessful in obtaining
individual patient data from the trials included in their
meta-analysis [8, 16]. Gebski et al. were able to evaluate
individual patient data from two studies [6].
Data extracted from the primary studies may differ. It is
therefore important to identify the review that takes into
account the outcome measure most relevant to the clinical
question. As shown in Table 1, the outcome measures vary
widely between studies. But there may also be differences
in data extraction due to human error, biased extraction, or
misprints. Only in the study by Urschel et al. did two
independent researchers perform the data extraction, and
this was done in duplicate (not blinded) [9].
Quality of the primary studies
Before analyzing all trials together, the design of the trial,
the treatments, the population of patients included, the
quality of the trial, and a summary of the results must be
assessed. It is important to ﬁnd out if the trials are similar
enough to be combined, to get an understanding of the
types of patients studied and ﬁnally, to assess the quality
and availability of the data. The authors from the meta-
analyses should also state the reason for excluding trials
from the analysis.
Studies can be included in a meta-analysis that are not
well-designed controlled trials. A good meta-analysis of
badly designed studies will still result in bad statistics:
garbage in, garbage out [17]. Given the rather limited
number of RCTs on the role of neoadjuvant CRT in
esophageal cancer, the article selection process was
designed to be inclusive as opposed to exclusive in all
reviews, and trials were not excluded because of trial
quality. However, assessment of the methodological
quality of the trials included is an essential component of
systematic reviews [18]. How the quality of the primary
studies was assessed (by what method) should be included
in a review. Reviews that address these issues are likely to
be more rigorous that those that ignore trial quality. In only
two of the reviews in this report was primary trial quality
assessment performed (Urshel et al. and Fiorina et al.); the
other four reviews ignore this important issue. In the study
of Urshel et al. the quality of the included trials was rather
poor (mean score of 2.1) as judged on a 5-point Jadad scale
[9, 19]. The authors explain this by saying that it is likely
due to the importance placed on blinding in this scoring
system, and the inherent difﬁculty in blinding treatment,
such as in CRT trials. Furthermore, most of the included
primary studies did not report details of the randomization
methods. Gebski et al. judged, however, that allocation
concealment was not assumed to be compromised and they
did not incorporate a quality assessment in their review [6].
Fiorica et al. stated that three studies did not clearly deﬁne
criteria for handling withdrawal [7].
There are no RCTs that have a sufﬁciently large sample
size. In only two studies were more than 100 patients
randomized. The EORCT study by Bosset et al. reported on
293 patients and the study of Burmeister et al. included 256
patients [20, 21]. Moreover, it should be underscored that
these two studies are not similar: sequential CRT was given
in the study of Bosset et al. whereas Burmeister et al.
applied concurrent CRT.
Two trials show a survival beneﬁt of neoadjuvant CRT,
but these trials have also been criticized by many investi-
gators [22, 23]. The most recent of the two, by Tepper
et al., was stopped prematurely due to lack of accrual [24].
Although the trial indicates a beneﬁt in overall survival and
progression-free survival for patients treated with trimo-
dality therapy, the statistical methods used can be heavily
criticized [25]. It is clear that a phase II clinical trial
designed to deﬁnitively indicate whether chemoradiother-
apy plus surgery is superior to surgery alone is difﬁcult to
conduct. Consequently, the results of meta-analyses to
answer this question gain increased importance. In both
studies reporting survival, that of the control group (no
CRT) was very low, with a 5-year survival rate of 16% and
a 3-year survival of 6%; also, the quality of the surgery
performed is open for discussion.
Two other published series on neoadjuvant chemoradi-
ation are from Lee et al. and from Burmeister et al. [21,
26]. The latter study is the largest with concurrent che-
motherapy and radiotherapy followed by surgery. How-
ever, this study can also be criticized. Tumor staging was
based on ‘‘old-fashioned’’ staging modalities, and no
stratiﬁcation for tumor type was performed. There was a
low percentage of complete pathological response in the
adenocarcinomas (7.5%), and 15% of the included patients
World J Surg (2009) 33:2606–2614 2609
123received a different chemotherapy regime. Furthermore,
postoperative radiotherapy was allowed but not standard-
ized. Finally, a rather large number of R1/R2 resections
was reported (59%) in the control (surgery only) group.
Clearly, this study does not reﬂect current surgical out-
comes in medium- to high-volume esophageal cancer
centers.
Clinical heterogeneity
In a meta-analysis, data from several studies are combined
to come to an estimation of the overall effect of a treat-
ment. This is called pooling of the data from the individual
trials. In order to do so the trials need to be homogeneous
in terms of clinical as well statistical methods. Clinical
heterogeneity exists when the patients, the interventions, or
the outcome measures are not similar. As already brieﬂy
mentioned, there is wide variation between the included
primary trials in patient characteristics, in tumor histology,
and in radiotherapy and chemotherapy regimens (Table 3).
Also, surgical technique was not uniform across the stud-
ies. Although the debate over the transthoracic versus the
transhiatal approaches continues, there has been evidence
to support the equality of these techniques with respect to
outcome [27]. However, on long-term follow-up, patients
with adenocarcinomas of the distal esophagus may beneﬁt
from a transthoracic approach as opposed to transhiatal
resection [28]. But perhaps more important, there is con-
siderable heterogeneity observed both in the radiotherapy
and in the chemotherapy protocols among studies. Vari-
ability in chemotherapy protocols among trials was found
in number and type of agents administered and the dose
and scheduling of the drugs. Doses of radiotherapy in some
studies are considered suboptimal by today’s standards.
Not only the total dose varies between studies (between
35 Gy and 50.4 Gy), but also the daily dose differs
(between 1.75 Gy and 3.70 Gy) and the number of frac-
tions (between 10 and 30) administered over 2–4 weeks.
Also, the timing of delivery varied: sequential in three
studies versus concurrent in seven studies. It is difﬁcult to
determine whether differing results with respect to overall
survival rate are due to more effective CRT regimens in
some trials.
Stage at time of diagnosis by study treatment arm was
unavailable in one case [29]. Greer et al. noticed a greater
proportion of patients with advanced disease (stage II or
greater) in the surgery-alone arm [16]. However, only two
studies enrolled patients with advanced disease [15, 20],
and Walsh et al. reported only the stage of disease post-
CRT [30]. This may have resulted in an overall ‘‘down-
staging’’ of patients in the CRT group, giving a false
impression that patients in the surgery-alone arm had more
advanced disease. Uncertainty about the true baseline
characteristics of patients limits our ability to interpret the
effect of preoperative stage on outcome.
How to handle heterogeneity?
Judgments based on clinical and biological understanding
of the disease and processes and mechanisms of action of
interventions can be used to determine whether it makes
sense to pool the results of particular studies with those of
other studies. This issue rests with the clinician. Reviews
that address whether results can be combined and that
make efforts to test the underlying assumptions in choosing
the statistical method for pooling data are probably more
credible than reviews that ignore such issues [31]. If the
results from the primary trials widely differ, despite the
assumption of clinical homogeneity, this is called statistical
heterogeneity. This can be due to differences in outcome
measures between the trials, true differences in outcome
between the trials or differences in methodological quality
between the trials.
To test for heterogeneity one can perform an analysis
(test). However, in the meta-analyses on neoadjuvant CRT
this test is rather unreliable and lacks statistical power due
to the few studies included [2, 7]. One can also ignore
statistical heterogeneity by not adjusting the statistical
method. This is called ‘‘ﬁxed-effects model.’’ The down-
side of applying this method is that it frequently shows
signiﬁcant results with small conﬁdence intervals com-
pared to the ‘‘random-effects model.’’ This latter model,
however, corrects for heterogeneity, is a more conservative
estimator and minimizes the risk of erroneously assigning
beneﬁt to the treatment group if no beneﬁt really exist [2].
Kaklamanos et al. assumed that the studies on neoadju-
vant CRT are homogenous and used a ﬁxed-effects model
for calculating their summary estimates [8]. Urschel et al.
considered that a ﬁxed-effects model was not methodo-
logically sound given the obvious heterogeneity of the trials
[9]. Also Greer et al. used a random-effects model to cal-
culate a summary value for relative risk of death [16]. These
authors also tested for homogeneity across studies. Fiorica
et al. calculated the overall odds ratios with models based
both on ﬁxed effects and random-effects assumptions [7].
After calculation of the overall effect in a meta-analysis,
one can exclude trials of higher and/or lower methodo-
logical quality and measure the effect on the outcome. This
is called sensitivity or robust analysis. If the outcome
measure of the pooled analysis changes a lot, the result of a
review needs to be interpreted with the highest caution.
However, this analysis is not a standard or prerequisite part
of a meta-analysis. The robust analysis of Fiorica et al.
showed that statistical signiﬁcance for overall mortality
was lost after exclusion of either the trial by Walsh et al. or
the trial by Urba et al. [29, 32].
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123In the study by Gebski et al., potential clinical hetero-
geneity because of different follow up durations between
studies starting earlier and later was accounted for by use
of hazard ratio as the effect estimate, because it takes into
account the duration of follow-up [6]. The authors per-
formed a test of heterogeneity between studies started
before 1994 and after 1993. This test suggested that there
was no heterogeneity and that combining all studies is
appropriate. The same group also excluded one study
without changing the result for the overall effect of CRT,
which remains signiﬁcant. If the two unpublished studies
are excluded from this analysis, then there is no appre-
ciable difference in the ﬁndings.
Another possibility is to exclude heterogeneity by per-
forming subgroup analyses. This should however only been
done based on a predeﬁned plan at the time of designing
the meta-analysis in order to avoid a ﬁshing experiment
and the risk for false-positive results. Subgroup analyses
performed afterwards that have not been written in the
initial study protocol can only be seen as hypothesis
generating.
Subgroup analysis
Adenocarcinomas versus squamous cell carcinomas
Fiorica et al. found that the effect of preoperative CRT on
overall survival is much more pronounced and statistically
signiﬁcant in patients with adenocarcinoma [7]. At the
same time they warn that the sample size of this explor-
atory subgroup analysis is small (data obtained from only
two trials). If only RCTs addressing squamous cell cancers
were considered, the 3-year survival advantage of neoad-
juvant CRT plus surgery was less apparent and became
nonsigniﬁcant in one study [9]. Kaklamanos et al. did not
ﬁnd evidence to suggest that tumor histology is associated
with variations in the effect of neoadjuvant treatment on 2-
year survival [8]. Finally, by using the raw data from two
trials, Gebski et al. found a beneﬁt of CRT over surgery for
both histological tumor types (both concurrent CRT
schedules) [6].
Concomitant versus sequential radiation therapy
The optimal radiation fraction, dose, and time of delivery
are not known. Higher postoperative morbidity was
observed in two RCTs in which a fraction dose of[2G y
was delivered [20, 30]. With respect to the time of delivery,
concomitant radiotherapy with chemotherapy has theoret-
ical advantages. The aim of combining neoadjuvant che-
motherapy and radiotherapy is to use the radiosensitizing
effect of chemotherapy to reduce tumor size and to
maximize local control [33]. Fiorica et al. concluded that
the available information seems inadequate to determine
whether a concomitant regimen of CRT is better than
induction chemotherapy followed by radiotherapy [7].
Urshel et al. as well as Gebski et al. found that
sequential chemoradiation did not demonstrate a survival
beneﬁt at 3 years, as opposed to concurrent CRT [6, 9].
Concurrent CRT had a similar signiﬁcant beneﬁt for both
histological types [6]. To date no trial has been performed
that compared CRT delivered sequentially or concomi-
tantly to resolve this apparent contradiction.
Treatment-related mortality and morbidity
Kaklamanos et al. could not ﬁnd a signiﬁcant difference in
treatment-related mortality between neoadjuvant CRT plus
surgery versus surgery alone [8]. The overall rate of post-
operative adverse events was not different between the
CRT group and the surgery alone group. However, there
was a signiﬁcant effect of CRT on postoperative mortality
(90 days) with an odds ration (OR) of 2.1. This increased
risk was conﬁrmed in an analysis of observational data
including 3,592 patients [34]. Excluding the trials of Bosset
et al. [20] resulted in loss of signiﬁcance [7]. The rate of
adverse events was not signiﬁcantly different between the
two treatment arms, but a trend in favor of surgery alone
was described for both operative mortality and all treat-
ment mortality.
Are the results clinically relevant?
The magnitude of the overall effect of neoadjuvant CRT is
considered clinically relevant by Fiorica et al. [20]. With a
number needed to treat (NNT) of 10, preoperative CRT
prolongs 3-year overall survival versus surgery alone. On
the contrary, there is evidence that CRT signiﬁcantly
increases morbidity and postoperative mortality (number
needed to harm; NNH = 25). But fewer patients need to be
treated to beneﬁt from the treatment over the long term
than need to be treated to be harmed immediately post-
surgery. Gebski et al. also calculated the number of patients
needed to treat to save one life with a (theoretical) patient
population risk if the 2-year survival was 20% (high risk),
35% (moderate risk), and 50% (low risk). Based on their
ﬁndings of a relative risk reduction of 19% for CRT, the
absolute risk reduction was greatest in those at high risk
who were receiving CRT: to prevent one death, seven
patients would need treatment (NNT = 7). The smallest
beneﬁt was for patients with a low risk who were receiving
CRT: NNT = 10 [6].
With more rigorous staging, e.g., using positron emission
spectroscopy/computed tomography (PET-CT) pretreatment
2612 World J Surg (2009) 33:2606–2614
123stage stratiﬁcation, and more complete resection of the
primary tumor and associated lymph nodes, the effect from
the neoadjuvant therapies is, however, likely to be less. It
might lead to a smaller treatment effect in terms of absolute
risk reduction but is unlikely to hold for relative treatment
effects [6]. However, to identify individuals with operable
esophageal cancer who are most likely to beneﬁt from
CRT, future trials will need to carefully stratify patients for
the stage of disease by use of EUS, high quality CT, and
PET scanning.
Finally, no correction for the extra time that CRT brings
for patients was made in any of the trials or meta-analyses.
For instance, if chemoradiation yields a survival beneﬁt of
a few months and it also costs a few months of extra time
for recovery compared with surgery alone, the beneﬁt
would be completely lost.
Summary and conclusions
The pace of medical research, our increasing need for
valid, relevant health care information, and our limited
resources to ﬁnd, appraise and apply this information
underscore the need for rigorous reviews to guide health
care decisions. There has been exponential growth in sys-
tematic reviews, and this has led to an increase in the
number of reviews that address similar therapeutic prob-
lems and that yield discordant results [3].
Meta-analyses of evidence can be criticized because of
heterogeneity among the trials included in a meta-analysis.
Furthermore, the conclusions from meta-analysis depend
on the selection of the statistical technique used. This was
recognized in the late 1990s. Also the reporting of meta-
analyses was frequently shown to be of inferior quality. In
1999, the so-called QUOROM (Quality of Reporting of
Meta-Analyses) statement was published to address stan-
dards for improving the quality of reporting of meta-anal-
yses of clinical RCTs [11].
The most recently published meta-analysis which
includes 10 RCTs showed a signiﬁcant survival beneﬁt for
preoperative CRT in esophageal cancer patients [6]. Can
this study convince us to adopt this regime for our patients?
In other words: is this meta-analysis of sufﬁcient quality?
Does it meet the A1 level of evidence? Studies with an A1
level of evidence can de deﬁned as systematic reviews that
have included homogeneous studies with level A2 evi-
dence. Studies that are deﬁned as level A2 evidence are
randomized controlled clinical trials of good quality, with
an adequate sample size. It is questionable whether the
primary RCTs included in that meta-analysis can be con-
sidered as such. Most of them were started before 1994,
and hence methods for diagnosis, staging, treatment
delivery, and outcome measurement reﬂect clinical prac-
tice during that period. Pretreatment staging did not include
routine CT scanning in some primary trials, and stage
stratiﬁcation was attempted in very few. Furthermore, trial
design issues (effect size justiﬁcation, statistical power,
sample size, and study duration) were not rigorously
applied. This has resulted in many small trials being done
with negative results.
When we look at histological types, squamous cell
cancers are overrepresented in these studies: 70% vs. 30%
adenocarcinomas. Given the increasing incidence of ade-
nocarcinomas and the fact that nowadays in the West more
than half of the esophageal cancers are adenocarcinomas,
the results of these studies have to be interpreted with care.
With regard to the adenocarcinomas: these tumors do not
show a difference in 2-year survival in one study [8]. A
number of studies have been prematurely stopped due to
lack of accrual and as such are underpowered.
Publication bias could have an effect, although exten-
sive screening of the literature by some authors, in addition
to personal contacts made directly with principal investi-
gators, make this issue less likely. Finally, no correction for
the extra time that chemoradiotherapy brings to patients
was made in any of the trials or meta-analyses. For
instance, if chemoradiation yields a survival beneﬁt of a
few months and it also costs a few months of extra time for
recovery compared with surgery alone, then the beneﬁt
would be completely lost.
Studies have shown that neoadjuvant treatment may
downstage the tumor and induce complete pathological
response, but only a few trials reported separate survival
data on patients who responded to treatment. Although
separate analyses have not been performed in the pub-
lished meta-analyses, the results suggest that neoadjuvant
therapy may offer a survival beneﬁt in this group of
patients. It is likely that any such improvement would be
greater for patients with a complete pathological response.
Therefore, the results of other phase III RCTs that are
underway may contribute to a better understanding of the
role of neoadjuvant treatment for resectable cancer of the
esophagus and help to identify patient subgroups who
would beneﬁt. The current data also strongly indicate the
need for designing future trials considering the clinical
difference between adenocarcinomas and squamous cell
carcinomas and its potential inﬂuence on patient response
to therapy.
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